Navigation Links
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Date:11/7/2007

golimumab 100 mg, respectively, achieved PASI 75 at week 14, compared with 3 percent of patients receiving placebo (P < 0.001). At week 24, PASI 75 responses improved to 56 percent (golimumab 50 mg) and 66 percent (golimumab 100 mg), compared with 1 percent of placebo patients (P < 0.001). In additional analyses, patients receiving golimumab 50 mg and golimumab 100 also experienced improvements in nail psoriasis as measured by NAPSI and these improvements were sustained over time.

"These Phase 3 data show that once monthly subcutaneous administrations of golimumab 50 mg and golimumab 100 mg significantly improved articular and psoriatic manifestations in patients with psoriatic arthritis," said Jerome A. Boscia, MD, senior vice president, Clinical Research and Development, Centocor, Inc. "We are encouraged by these results and believe golimumab holds great promise as a new anti-TNF-alpha therapy for physicians and patients in need of additional therapeutic options."

Disease Activity and Physical Function Improvements

The majority of golimumab-treated patients in the study were classified as good or moderate responders as measured by the Disease Activity Score 28 (DAS28), which measures tender and swollen joints and overall disease activity including measurement of serum C-reactive protein (CRP) levels. After 14 weeks of treatment, 66 percent of patients receiving golimumab 50 mg were DAS28 responders, as were 67 percent of patients receiving the 100 mg dose, compared with 24 percent of patients receiving placebo (P < 0.001). At week 24, 64 percent and 78 percent of patients receiving golimumab 50 mg and 100 mg, respectively, were DAS28 responders, compared with 24 percent of patients receiving placebo (P < 0.001).

Patients receiving golimumab in the study also experienced significant improvements in physical function, as measured by the Health Assessment Questionnaire (HAQ). At week 14, patients receiving golimumab 50 mg experienced a mean i
'/>"/>

SOURCE Centocor Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... -- For the past 15 years, there has been an average ... alone (U.S. Census Bureau 2012). Of course, not every accident is ... are quite a few where the car occupants can get stuck ... seatbelt release button or occupant injury. One may ... their lifetime but may still be "lucky" enough to come upon ...
(Date:3/2/2015)... Colo. , March 2, 2015 ... close of their transactions, Array BioPharma Inc. (NASDAQ: ... binimetinib and encorafenib definitive agreements with Novartis.  Along ... receive an upfront payment of $85 million from ... Array, noted, "With the close of the Novartis-GSK ...
(Date:3/2/2015)... YORK , March 2, 2015 Leading ... are kicking off the 2015 One Million ... month-long national campaign will raise awareness and funds for ... more than one million colorectal cancer survivors living in ... this disease with great strength and courage every day. ...
Breaking Medicine Technology:New SuperVizor, an Automobile Escape Tool, Ensures the Safety of Drivers and Passengers on the Road 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 3Array Announces Completion Of Binimetinib And Encorafenib Transactions 4Array Announces Completion Of Binimetinib And Encorafenib Transactions 5Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 2Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 3Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 4Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 5
... Boehringer Ingelheim and Eli Lilly and Company ... positive opinion from the European Medicines Agency,s (EMA) medicinal ... (to be marketed under the trade name Trajenta® in ... diabetes. If adopted by the European Commission, linagliptin will ...
... Environment Concepts (SMEV.PK), the manufacturer and developer of ... today that the Company has made the first delivery ... (Elements), a women,s health and fitness center, in ... the two companies earlier this year.  With the SpaCapsule ...
Cached Medicine Technology:Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe 2Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe 3Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe 4Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe 5Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe 6Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe 7SpaCapsule Manufacturer Delivers First Order to Elements Diet and Fitness Under Preferred Vendor Agreement 2SpaCapsule Manufacturer Delivers First Order to Elements Diet and Fitness Under Preferred Vendor Agreement 3SpaCapsule Manufacturer Delivers First Order to Elements Diet and Fitness Under Preferred Vendor Agreement 4
(Date:3/2/2015)... (PRWEB) March 02, 2015 Robins & ... In conjunction with Women in Construction Week (March 1-7, ... or NAWIC) and National Women’s History Month, Robins & ... positively affect the company and the construction industry as ... team, to the dozens of roles in between, each ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 The Workgroup ... authority on the use of health IT to create ... paper, “ICD-10 Testing for Small Providers.” The white paper ... a starting point for ICD-10 testing by focusing on ... to ensure compliance with the October 1, 2015 implementation ...
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual ... for people across the country to unite, raise awareness, ... live their best lives. MS Awareness Week is a special ... join the Society’s vision of a world free of MS. ... of the central nervous system, interrupts the flow of information ...
(Date:3/2/2015)... Four Seasons Resort Maui at Wailea, the ... this year, having officially opened its doors on March 2, ... honoring over 70 employees who started on Day 1 and ... approximately 400 original employees. The celebration will be a ... , This Four Seasons flagship resort, the first resort ...
(Date:3/2/2015)... 2015 What are the best practices ... references? When are interviews scheduled, how can physicians best ... training and practicing physicians who are looking for new ... more at the PracticeLink Physician Career Advancement Workshop and ... Fair is from 5:30 to 8:30 p.m. at the ...
Breaking Medicine News(10 mins):Health News:Robins & Morton Recognizes Women In Construction 2Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2
... proof cancer will spread to the healthy second ... -- Women diagnosed with breast cancer who have a ... breast removed as a preventive measure. , The rate ... than doubled from 1998 to 2003, according to a ...
... JOSE, Calif., Oct. 22 The start of the,patent ... ) against,three endovenous laser competitors, Diomed, AngioDynamics and Vascular,Solutions, ... of,October 29. The delay is due to a busy ... to identify potential new trial start dates. At,the conference, ...
... Dialysis Corporation,of America (Nasdaq: DCAI ) ... 2007 earnings after the close of the markets ... America owns and operates freestanding kidney,hemodialysis centers located ... and Virginia, and provides in-hospital,dialysis services on a ...
... to Act in Good Faith with Employees, Leads,District ... The American Federation,of Government Employees (AFGE), which represents ... Health System (NF/SGVHS), today,criticized the Department of Veterans ... with its employees by failing to honor the ...
... Oct. 22 AtriCure, Inc.,(Nasdaq: ATRC ), a ... cardiac surgical devices, will release,its financial results for the ... AtriCure will host a conference call at 10:00 ... quarter 2007 results. A live web cast of,the conference ...
... Cereal cuts cardiovascular risk, as do fruits, veggies, research ... rich in whole grains, fruits, vegetables and even a ... studies show. , In one study, regular consumption of ... for male American physicians. , Another study, this time ...
Cached Medicine News:Health News:More Women Choosing 'Preventive' Double Mastectomy 2Health News:More Women Choosing 'Preventive' Double Mastectomy 3Health News:Delay in Start of VNUS Patent Litigation and Court Ruling on Summary Judgment Motion 2Health News:Dialysis Corporation of America Announces Third Quarter 2007 Earnings Release Date 2Health News:Mismanagement at North Florida/South Georgia Veterans Health System Results in Chronic Staff Shortages, Budget Issues 2Health News:AtriCure Announces Web Cast and Conference Call of Third Quarter 2007 Financial Results 2Health News:Whole Grains Do a Heart Good 2Health News:Whole Grains Do a Heart Good 3
The Easy Wrap Apron is now available with an attached Thyroid Collar. The Thyroid Collar is held on with velcro so it adjusts to fully protect the neck. This Apron with Collar is available in 5mm lea...
... knee system is a long ... a clinically proven design. Available ... anatomically correct cruciate retaining configurations. ... ease of identification keeps the ...
... The Genesis II® Total Knee System will ... far more is possible with less - ... while fully addressing both clinical and cost ... these design goals, giving surgeons creative solutions ...
Cementless hip system...
Medicine Products: